Animal models for predicting the efficacy and side effects of antipsychotic drugs

Glutamatergic Animal Models of Schizophrenia

(2012) Corina Bondi et al.   CURRENT PHARMACEUTICAL DESIGN

Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap

(2012) Judith Pratt et al.   NATURE REVIEWS DRUG DISCOVERY

Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules

(2012) Akihiro Mouri et al.   NEUROBIOLOGY OF DISEASE

Schizophrenia: Treatment Targets Beyond Monoamine Systems

(2011) Hisham M. Ibrahim et al.   Annual Review of Pharmacology and Toxicology

The role of serotonin receptors in the action of atypical antipsychotic drugs

(2011) HY Meltzer et al.   CURRENT OPINION IN PHARMACOLOGY

Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?

(2011) Bart A. Ellenbroek   NEUROPHARMACOLOGY

Incidence of Tardive Dyskinesia With Atypical Versus Conventional Antipsychotic Medications

(2010) Scott W. Woods et al.   JOURNAL OF CLINICAL PSYCHIATRY

Behavioral Indices in Antipsychotic Drug Discovery

(2010) R. D. Porsolt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The environment and schizophrenia

(2010) Jim van Os et al.   NATURE

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

(2010) Franz X. Vollenweider et al.   NATURE REVIEWS NEUROSCIENCE

Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice

(2010) J J Crowley et al.   PHARMACOGENOMICS JOURNAL

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism

(2010) Joanna C. Neill et al.   PHARMACOLOGY & THERAPEUTICS

Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress

(2010) Jerome Brunelin et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Conditioned Avoidance Response in the Development of New Antipsychotics

(2009) M-L. Wadenberg   CURRENT PHARMACEUTICAL DESIGN

Schizophrenia

(2009) Jim van Os et al.   LANCET

Top–down modulation of prepulse inhibition of the startle reflex in humans and rats

(2009) Liang Li et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

Serotonin depletion in the dorsal and ventral hippocampus: Effects on locomotor hyperactivity, prepulse inhibition and learning and memory

(2008) Wendy Adams et al.   NEUROPHARMACOLOGY

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection

(2008) J. A. Lieberman et al.   PHARMACOLOGICAL REVIEWS

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice

(2007) Juliana V. Leite et al.   EUROPEAN JOURNAL OF PHARMACOLOGY